Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (95)

« Back to Publications

8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.

Pant D. et al, (2027), Lancet Glob Health

Impact of dosing interval on immunogenicity following a heterologous typhoid conjugate vaccine booster in Nepalese children: an observational study.

Zhang Y. et al, (2026), J Infect

COVID-19 vaccine effectiveness and SARS-CoV-2 variants in Nepal: Test-negative case-control study and genetic sequencing (COVVAR Nepal)

Pokhrel B. et al, (2026), Vaccine X, 31

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.

Ebrahimi N. et al, (2026), Vaccine, 88

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine.

Kelleher K. et al, (2026), BMJ Open, 16

A Controlled Human Malaria Infection model for relapsing Plasmodium vivax

Duncan ADS. et al, (2026)

The association between vaccine coverage and herd protection: exploratory analyses of a cluster-randomised trial of Vi conjugate vaccine.

Zhang Y. et al, (2026), EClinicalMedicine, 94

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.

Bijukchhe SM. et al, (2026), Lancet Infect Dis

Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.

Kelly E. et al, (2026), J Infect, 92

Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants

Businge GB. et al, (2025)

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.

Janani L. et al, (2025), J Infect, 91

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Li G. et al, (2025), Vaccine, 62

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9

Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model.

Ashton PM. et al, (2025), Microbiome, 13

Load More

1
2
3
4
5
6
7